StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research note published on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Trading Down 6.5 %
RDHL stock opened at $3.60 on Tuesday. RedHill Biopharma has a fifty-two week low of $3.01 and a fifty-two week high of $20.27. The business’s fifty day moving average price is $5.81 and its two-hundred day moving average price is $14.98.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC bought a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
See Also
- Five stocks we like better than RedHill Biopharma
- The Role Economic Reports Play in a Successful Investment Strategy
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- ESG Stocks, What Investors Should Know
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
